Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-224-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.09 million
Profitability
Miscellaneous
Employees70
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Organovo (NASDAQ:ONVO) Frequently Asked Questions
What is Organovo's stock symbol?
Organovo trades on the NASDAQ under the ticker symbol "ONVO."
How were Organovo's earnings last quarter?
Organovo Holdings Inc (NASDAQ:ONVO) posted its quarterly earnings results on Thursday, August, 8th. The medical research company reported ($0.05) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.05). The medical research company earned $0.67 million during the quarter, compared to analyst estimates of $0.77 million. Organovo had a negative net margin of 831.99% and a negative return on equity of 69.51%. View Organovo's Earnings History.
When is Organovo's next earnings date?
What price target have analysts set for ONVO?
1 equities research analysts have issued 12-month price objectives for Organovo's stock. Their forecasts range from $2.50 to $2.50. On average, they expect Organovo's stock price to reach $2.50 in the next year. This suggests a possible upside of 770.8% from the stock's current price. View Analyst Price Targets for Organovo.
What is the consensus analysts' recommendation for Organovo?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Organovo.
Has Organovo been receiving favorable news coverage?
News articles about ONVO stock have been trending neutral recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Organovo earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Organovo.
Are investors shorting Organovo?
Organovo saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 4,600,000 shares, a decline of 18.6% from the August 30th total of 5,650,000 shares. Based on an average trading volume of 709,300 shares, the short-interest ratio is currently 6.5 days. Approximately 3.6% of the company's shares are sold short. View Organovo's Current Options Chain.
Who are some of Organovo's key competitors?
Some companies that are related to Organovo include X4 Pharmaceuticals (XFOR), Oncobiologics (ONS), Axcella Health (AXLA), Nantkwest (NK), Acorda Therapeutics (ACOR), Novavax (NVAX), Gamida Cell (GMDA), Jounce Therapeutics (JNCE), Aptose Biosciences (APTO), Adaptimmune Therapeutics (ADAP), Windtree Therapeutics (WINT), Allena Pharmaceuticals (ALNA), Brainstorm Cell Therapeutics (BCLI), Fennec Pharmaceuticals (FENC) and Polarityte (PTE).
What other stocks do shareholders of Organovo own?
Who are Organovo's key executives?
Organovo's management team includes the folowing people:
- Mr. Taylor J. Crouch, CEO, Pres & Director (Age 59)
- Mr. Craig Kussman, Chief Financial Officer (Age 60)
- Ms. Jennifer Kinsbruner Bush, Sr. VP, Compliance Officer, Gen. Counsel & Corp. Sec. (Age 44)
- Mr. Paul Gallant, Gen. Mang. (Age 54)
- Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications
How do I buy shares of Organovo?
Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Organovo's stock price today?
One share of ONVO stock can currently be purchased for approximately $0.29.
How big of a company is Organovo?
Organovo has a market capitalization of $37.40 million and generates $3.09 million in revenue each year. The medical research company earns $-26,640,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. Organovo employs 70 workers across the globe.View Additional Information About Organovo.
What is Organovo's official website?
How can I contact Organovo?
Organovo's mailing address is 6275 NANCY RIDGE DRIVE SUITE 110, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]
MarketBeat Community Rating for Organovo (NASDAQ ONVO)
MarketBeat's community ratings are surveys of what our community members think about Organovo and other stocks. Vote "Outperform" if you believe ONVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
